10th International Symposium on
Medical Information and Communication Technology (ISMICT'16)
March 20-23, 2016

Worcester Polytechnic Institute
100 Institute Rd
Worcester, MA, USA

Myriam Armant, TransLab, Boston Childrens Hospital and Dana Farber Cancer Institute
misra   Myriam Armant, PhD is the director of the TransLab at Boston Children's Hospital (BCH), which is an innovative clinical and translational platform that bridges scientific discovery and clinical practice. Dr. Armant has over a decade of experience and expertise in cell and gene therapy manufacturing process and product development. Under her leadership, the TransLab has supported multiple cell therapy trials by delivering validated standard operating procedures (SOPs), product-specific characterization and acceptance criteria to ensure product safety, identity, purity and strength. Her lab is also in charge of technology transfer to GMP- cell processing facilities and offers regulatory support generating the Chemistry, Manufacturing, and Controls (CMC) section of the Investigational New Drug (IND) Application. The TransLab has enabled a diverse portfolio of phase I/II and III clinical trials covering cancer immunotherapy, regenerative medicine and gene therapy. Ten different clinical trials (both single and multicenter, academic and industry-sponsored) have used manufacturing processes developed by the TransLab. Over the past five years, she has contributed to establishing a gene therapy program at BCH. More recently, she has extended the role of the TransLab to support correlative studies and patient monitoring on clinical trials, by offering a comprehensive battery of cellular and molecular assays.